Molecular structure of SR 27897, CAS Number: 136381-85-6
SR 27897 (CAS 136381-85-6)
Application:
SR 27897 is an effective non-peptide antagonist of CCK
CAS Number:
136381-85-6
Molecular Weight:
411.86
Molecular Formula:
C20H14ClN3O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SR 27897 is an effective non-peptide antagonist of CCK1 (cholecystokinin) receptors. CCK is a neuroendocrine peptide described to play an important role in cell growth, cell proliferation, and other biological functions. Plasma leptin studies indicate that SR 27897 elevates plasma concentration of plasma and leptin in rats. SR 27897 inhibits CCK-AR.
SR 27897 (CAS 136381-85-6) References
- Exogenous CCK and gastrin stimulate pancreatic exocrine secretion via CCK-A but also via CCK-B/gastrin receptors in the calf. | Le Dréan, G., et al. 1999. Pflugers Arch. 438: 86-93. PMID: 10370091
- Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding. | Gouldson, P., et al. 1999. Eur J Pharmacol. 383: 339-46. PMID: 10594328
- Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S. | Gouldson, P., et al. 2000. Eur J Pharmacol. 389: 115-24. PMID: 10688974
- Inhibition of the hypothalamic-pituitary-adrenal axis in food-deprived rats by a CCK-A receptor antagonist. | Ruiz-Gayo, M., et al. 2000. Br J Pharmacol. 129: 839-42. PMID: 10696079
- The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor. | Gouldson, P., et al. 2000. Eur J Pharmacol. 400: 185-94. PMID: 10988332
- Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors. | Cano, V., et al. 2003. Br J Pharmacol. 140: 647-52. PMID: 14534148
- Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. | Carrillo, J., et al. 2009. Anticancer Drugs. 20: 527-33. PMID: 19407653
- Characteristics of the cholecystokinin-induced depolarization of pacemaking activity in cultured interstitial cells of Cajal from murine small intestine. | Lee, JH., et al. 2013. Cell Physiol Biochem. 31: 542-54. PMID: 23571358
- Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. | Gully, D., et al. 1993. Eur J Pharmacol. 232: 13-9. PMID: 7681406
- Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. | Poncelet, M., et al. 1993. Naunyn Schmiedebergs Arch Pharmacol. 348: 102-7. PMID: 8397341
Inhibitor of:
CCK-AR, and CCK-BR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SR 27897, 10 mg | sc-204298 | 10 mg | $183.00 | |||
SR 27897, 50 mg | sc-204298A | 50 mg | $867.00 |